The efficiency concept in pharmacodynamics

Clinical Pharmacokinetics

Volumn 36, Issue 5, 1999, Pages 375-389

  Alván, Gunnar ^a,c   Paintaud, Gilles ^b   Wakelkamp, Monique ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITÉ DE TOURS   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 8; BUMETANIDE; CHELATING AGENT; CHLOROTHIAZIDE; CIMETIDINE; FUROSEMIDE; LOOP DIURETIC AGENT; METHYLPREDNISOLONE; OPIATE; TORASEMIDE;

CONCENTRATION RESPONSE; DIURETIC ACTIVITY; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MATHEMATICAL MODEL; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 0033015970     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936050-00005     Document Type: Review

References (58)

1. 1. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-53
2. 2. Wagner JG. Kinetics of pharmacological response I: proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 1968; 20: 171-201
3. 3. Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982; 22: 69-74
4. 4. Burg MB. Tubular chloride transport and the mode of action of some diuretics. Kidney Int 1976; 9: 189-97
5. 5. Greger R, Wangemann P. Loop diuretics. Renal Physiol 1987; 10: 174-83
6. 6. Odlind B, Beermann B. Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 1980; 27: 784-90
7. 7. Wilson TW, Falk KJ, Labelle JL, et al. Effect of dosage regimen on natriuretic response to furosemide. Clin Pharmacol Ther 1975; 18: 165-9
8. 8. Beermann B. Kinetics and dynamics of furosemide and slow-acting furosemide. Clin Pharmacol Ther 1982; 32: 584-91
9. 9. Hammarlund MM, Odlind B, Paalzow LK. Acute tolerance to furosemide diuresis in humans: pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1985; 233: 447-53
10. 10. Alván G, Beermann B, Hjelte L, et al. Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis. Clin Pharmacol Ther 1988; 44: 436-41
11. 11. Prandota J, Smith IJ, Hilman BC, et al. Diuretic effect and disposition of furosemide in cystic fibrosis. Eur J Clin Pharmacol 1991; 40: 333-41
12. 12. Honari J, Blair AD, Cutler RE. Effects of probenecid on furosemide kinetics and natriuresis in man. Clin Pharmacol Ther 1977; 22: 395-401
13. 13. Homeida M, Roberts C, Branch RA. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man. Clin Pharmacol Ther 1977; 22: 402-9
14. 14. Chennavasin P, Seiwell R, Brater DC, et al. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 1979; 16: 187-95
15. 15. Sykes JB, editor. The concise Oxford dictionary of current English. 6th ed. Oxford: Oxford University Press, 1976
16. 16. Sherman MS. Theophylline improves measurements of respiratory muscle efficiency. Chest 1996; 110: 1437-42
17. 17. Alván G, Helleday L, Lindholm A, et al. Diuretic effect and diuretic efficiency after intravenous dosage of frusemide. Br J Clin Pharmacol 1990; 29: 215-9
18. 18. Holford NHG. Parametric models of the time course of drug action. In: van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action. Amsterdam: Elsevier; 1992: 61-70
19. 19. Alván G, Paintaud G, Eckernäs S-A, et al. Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect. Br J Clin Pharmacol 1992; 34: 47-52
20. 20. Paintaud G, Alván G, Eckernäs S-A, et al. The influence of food intake on the effect of two controlled release formulations of furosemide. Biopharm Drug Dispos 1995; 16: 221-32
21. 21. van Meyel JJ, Smits P, Russel FG, et al. Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. Clin Pharmacol Ther 1992; 51: 440-4
22. 22. Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115: 360-6
23. 23. Ferguson JA, Sundblad KJ, Becker PK, et al. Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther 1997; 62: 203-8
24. 24. Copeland JG, Campbell DW, Plachetka JR. Diuresis with continuous infusion of furosemide after cardiac surgery. Am J Surg 1983; 146: 796-9
25. 25. Lahav M, Regev A, Ra'anani P, et al. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992; 102: 725-31
26. 26. Dormans TPJ, van Meyel JJM, Gerlag PGG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28: 376-82
27. 27. Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med 1997; 25: 1969-75
28. 28. Aaser E, Gullestad L, Tølløfsrud S, et al. Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scand J Clin Lab Invest 1997; 57: 361-7
29. 29. Reiter PD, Makhlouf R, Stiles AD. Comparison of 6-hour infusion versus bolus furosemide in premature infants. Pharmacotherapy 1998; 18: 63-8
30. 30. Kramer WG, Smith WB, Ferguson J, et al. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol 1996; 36: 265-70
31. 31. Howard PA, Dunn MI. Severe musculoskeletal symptoms during continuous infusion of bumetanide. Chest 1997; 111: 359-64
32. 32. Wakelkamp M, Alván G, Paintaud G. Natriuretic efficiency of frusemide as a consequence of drug input rate. Br J Clin Pharmacol 1997; 43: 481-91
33. 33. Sommers DK, Meyer EC, Moncrieff J. The influence of co-administered organic acids on the kinetics and dynamics of frusemide. Br J Clin Pharmacol 1991; 32: 489-93
34. 34. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-78
35. 35. Gårdmark M, Brynne L, Hammarlund-Udenaes M, et al. Interchangeability and predictive performance of empirical tolerance models. Clin Pharmacokinet 1999 Feb; 36 (2): 145-67
36. 36. Wakelkamp M, Alván G, Scheinin H, et al. The influence of drug input rate on the development of tolerance to frusemide. Br J Clin Pharmacol 1998; 46: 479-87
37. 37. Wakelkamp M, Alván G, Gabrielsson J, et al. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 1996; 60: 75-88
38. 38. Fassos FF, Klein J, Fernandes D, et al. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous β-thalassemia. Clin Pharmacol Ther 1994; 55: 70-5
39. 39. Liliemark J, Peterson C. Pharmacokinetic optimisation of anti-cancer therapy. Clin Pharmacokinet 1991; 21: 213-31
40. 40. Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Clin Pharmacokinet 1997; 32: 324-43
41. 41. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333-40
42. 42. Capizzi RL. Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Invest New Drugs 1996; 14: 249-56
43. 43. Nishikawa K, Shibasaki C, Takahashi KT, et al. Treatment schedule dependency of antitumor effect of deoxyspergualin. Jpn J Antibiot 1991; 44: 917-25
44. 44. Liliemark JO, Paul CY, Gahrton CG, et al. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine. Cancer Res 1985; 45: 2373-5
45. 45. Paul C, Tidefelt U, Liliemark J, et al. Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time. Leuk Res 1989; 13: 191-6
46. 46. Dahlström BE, Paalzow LK, Segre G, et al. Relation between morphine pharmacokinetics and analgesia. J Pharmacokinet Biopharm 1978; 6: 41-53
47. 47. Paalzow G, Paalzow L. Opposing effects of apomorphine on pain in rats. Evaluation of the dose-response curve. Eur J Pharmacol 1983; 88: 27-35
48. 48. Scott JC, Cooke JE, Stanski DR. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiology 1991; 74: 34-42
49. 49. Lemmens HJM, Dyck JB, Shafer SL, et al. Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. Clin Pharmacol Ther 1904; 56: 261-71
50. 50. Hill HF, Mather LE. Patient-controlled analgesia. Clin Pharmacokinet 1993; 24: 124-40
51. 51. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 2577-83
52. 52. Matti H, Zhang L-C, van Strijen E, et al. Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection. Antimicrob Agents Chemother 1997; 41: 2083-8
53. 53. Mouton JW, Vinks AATMM, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997; 41: 733-8
54. 54. Carlsson M, Berntorp E, Bjorkman S, et al. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52
55. 55. Gobburu JVS, Jusko WJ. Role of dosage regimen in controlling indirect pharmacodynamic responses. Adv Drug Deliv Rev 1998; 33: 221-33
56. 56. Kleinbloesem CH, van Brummelen P, Danhof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41: 26-30
57. 57. Nyberg G, Gudnason T. Early tolerance with immediate-release isosorbide mononitrate. Physiologist 1998; 41: 281
58. 58. Alván G, Hammarlund-Udenaes MM, Odlind B. The validity of the sigmoid Emax model and efficiency concept in diuretic studies. Br J Clin Pharmacol 1991; 31: 210-1